Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Prevention, detection and treatment of AML relapse after allo-SCT

Thomas Schröder • 14 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia

Thomas Schröder, MD, of the University of Düsseldorf, Düsseldorf, Germany, discusses the prevention, detection and treatment of the acute myeloid leukemia (AML) relapse after allogeneic stem cell transplantation. This intervew took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Thomas Schröder

2:47
Management of relapse following alloHSCT in patients with AML and MDS
Thomas Schröder • 5 Oct 2021
1:54
New developments in AML treatment
Thomas Schröder • 5 Oct 2021
1:27
Progress in AML & research at the University of Düsseldorf
Thomas Schröder • 15 Mar 2019

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals